NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Dementia has become an all-important disease because the population is aging rapidly and the cost of health care associated with dementia is ever increasing. In addition to cognitive function impairment, associated behavioral and psychological symptoms of dementia (BPSD) worsen patient's quality of life and increase caregiver's burden. Alzheimer's disease is the most common type of dementia and both behavioral disturbance and cognitive impairment of Alzheimer's disease are thought to be associated with the N-methyl-D-aspartate (NMDA) dysfunction as increasing evidence of dysfunctional glutamatergic neurotransmission had been reported in behavioral changes and cognitive decline in Alzheimer's disease. We review the literature regarding dementia (especially Alzheimer's disease), BPSD and relevant findings on glutamatergic and NMDA neurotransmission, including the effects of memantine, a NMDA receptor antagonist, and NMDA-enhancing agents, such as D-serine and D-cycloserine. Literatures suggest that behavioral disturbance and cognitive impairment of Alzheimer's disease may be associated with excitatory neurotoxic effects which result in impairment of neuronal plasticity and degenerative processes. Memantine shows benefits in improving cognition, function, agitation/aggression and delusion in Alzheimer's disease. On the other hand, some NMDA modulators which enhance NMDA function through the co-agonist binding site can also improve cognitive function and psychotic symptoms. We propose that modulating NMDA neurotransmission is effective in treating behavioral and psychological symptoms of Alzheimer's disease. Prospective study using NMDA enhancers in patients with Alzheimer's disease and associated behavioral disturbance is needed to verify this hypothesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxidative Stress, Glutamate, and Neurodegenerative Disorders
Coyle, J. T., & Puttfarcken, P. (1993) · Science · doi:10.1126/science.7901908 · Cited by 3,762 · cited 1×
“Augmentation through the NMDAR-glycine binding site is preferred to avoid the excitotoxicity mediated through the glutamate binding site [106].”
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 1×
“…NSC-101-2325-B-039-009, NSC 101-2314- B-182A-073-MY2), National Health Research Institutes, Taiwan (NHRI-EX-101-9904NI), Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH101-TD-B-111-004), and China Medical University Hospital, Taiwan (DMR-99-120 and DMR-100-161).”
Blockade of NMDA Receptors and Apoptotic Neurodegeneration in the Developing Brain
Ikonomidou, C., Bosch, F., Miksa, M., Bittigau, P., Vöckler, J., Dikranian, K., Tenkova, T. I., Stefovska, V., Turski, L., & Olney, J. W. (1999) · Science · doi:10.1126/science.283.5398.70 · Cited by 2,055
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685 · cited 2×
“Besides, pharmacological blockade of NMDAR function leads to brain atrophy, impaired neuroplasticity, and learning disability [26-28].”
Schneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671 · cited 2×
“07 [145] and by another study demonstrating that mortality risks with typical antipsychotics are higher than with atypical antipsychotic agents in elderly patients [146].”
APP Processing and Synaptic Function
Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., & Malinow, R. (2003) · Neuron · doi:10.1016/s0896-6273(03)00124-7 · Cited by 1,644 · cited 1×
“Different from other NMDAR antagonists, memantine has been demonstrated to have beneficial effects for patients with moderate–to– severe AD, while not mild AD [101].”
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Risk of Death in Elderly Users of Conventional vs. Atypical Antipsychotic Medications
Wang, P. S., Schneeweiss, S., Avorn, J., Fischer, M. A., Mogun, H., Solomon, D. H., & Brookhart, M. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052827 · Cited by 959
Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia: A Review of the Evidence
Sink, K. M., Holden, K. F., & Yaffe, K. (2005) · JAMA · doi:10.1001/jama.293.5.596 · Cited by 910
Point and 5‐year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study
Steinberg, M., Shao, H., Zandi, P., Lyketsos, C. G., Welsh‐Bohmer, K. A., Norton, M. C., Breitner, J. C. S., Steffens, D. C., & Tschanz, J. T. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1858 · Cited by 780 · cited 2×
“Untreated BPSD contributes to over-medication [132, 133], premature institutionalization [128, 129], increased financial cost [120], decreased quality of life for both the caregivers and the patients [134, 135], significant stress to caregiver [136], nursing staff in residential facilities [137], and excess disability…”
Reversing EphB2 depletion rescues cognitive functions in Alzheimer model
Cissé, M., Halabisky, B., Harris, J., Devidze, N., Dubal, D. B., Sun, B., Orr, A., Lotz, G., Kim, D. H., Hamto, P., et al. (2011) · Nature · doi:10.1038/nature09635 · Cited by 433 · cited 1×
“On the other hand, Aβ aggregation interferes with NMDA neurotransmission, which may lead to cognitive function impairment as Aβ impairs NMDA–dependent LTP both in vivo and in vitro [85-87].”
Chen, Y., Durakoglugil, M. S., Xian, X., & Herz, J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914984107 · Cited by 368
Brigman, J. L., Wright, T., Talani, G., Prasad-Mulcare, S., Jinde, S., Seabold, G. K., Mathur, P., Davis, M. I., Bock, R., Gustin, R. M., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0640-10.2010 · Cited by 339 · cited 1×
“On the other hand, decrease of NR2B-containing receptor impairs LTP induction [20] and elimination of NR2B subunit function in area CA1 of hippocampus reduces neuron dendritic spine density and interferes with memory consolidation and learning [23, 24].”
Donepezil for the Treatment of Agitation in Alzheimer's Disease
Howard, R. J., Juszczak, E., Ballard, C. G., Bentham, P., Brown, R. G., Bullock, R., Burns, A. S., Holmes, C., Jacoby, R., Johnson, T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066583 · Cited by 327
Incidence of and risk factors for hallucinations and delusions in patients with probable AD
Paulsen, J. S., Salmon, D. P., Thal, L. J., Romero, R., Weisstein–Jenkins, C., Galasko, D., Hofstetter, C. R., Thomas, R., Grant, I., & Jeste, D. V. (2000) · Neurology · doi:10.1212/wnl.54.10.1965 · Cited by 254 · cited 1×
“For example, depression is common in the early stage of dementia and psychotic symptoms occur more frequently with disease progression [126, 127].”
Garcia-Alloza, M., Gil-Bea, F. J., Diez-Ariza, M., Chen, C. P. L.-H., Francis, P. T., Lasheras, B., & Ramirez, M. J. (2005) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2004.06.007 · Cited by 244
Gauthier, S., Loft, H., & Cummings, J. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1949 · Cited by 220
Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications
Richardson, R., Ledgerwood, L., & Cranney, J. (2004) · Learning & Memory · doi:10.1101/lm.78204 · Cited by 185 · cited 1×
“Besides, Dcycloserine, a partial agonist of NR1 subunit of NMDAR, can alleviate anxious symptoms in patients with anxiety disorder [194].”
Hippocampus-dependent learning facilitated by a monoclonal antibody or D-cycloserine
Thompson, L. T., Moskal, J. R., & Disterhoft, J. F. (1992) · Nature · doi:10.1038/359638a0 · Cited by 182
Fox, C., Crugel, M., Maidment, I., Auestad, B. H., Coulton, S., Treloar, A., Ballard, C., Boustani, M., Katona, C., & Livingston, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035185 · Cited by 173
Mishizen-Eberz, A. J., Rissman, R. A., Carter, T. L., Ikonomovic, M. D., Wolfe, B. B., & Armstrong, D. M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.09.016 · Cited by 156
Effect on memory processing by D-cycloserine, an agonist of the NMDA/glycine receptor
Flood, J. F., Morley, J. E., & Lanthorn, T. H. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90709-d · Cited by 153 · cited 2×
“Supporting neurotrophic/cognitive effects, D-cycloserine can improve cognitive functions in animal study [110-112].”
Konovalov, S., Muralee, S., & Tampi, R. R. (2007) · International Psychogeriatrics · doi:10.1017/s1041610207006540 · Cited by 126
Ye, X., & Carew, T. J. (2010) · Neuron · doi:10.1016/j.neuron.2010.09.013 · Cited by 121
Trinh, N.-H., Hoblyn, J., Mohanty, S., & Yaffe, K. (2003) · JAMA · doi:10.1001/jama.289.2.210 · Cited by 37
Chen, G., Chen, P., Tan, H., Ma, D., Dou, F., Feng, J., & Yan, Z. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.023 · Cited by 36 · cited 2×
“The modulation of AChE inhibitor on NMDA neurotransmission is impaired in amyloid precursor protein (APP) transgenic mouse model of AD [82].”
Cited by
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789
Nakajima, A., & Ohizumi, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143380 · Cited by 235
Hinrich, A. J., Jodelka, F. M., Chang, J. L., Brutman, D., Bruno, A. M., Briggs, C. A., James, B. D., Stutzmann, G. E., Bennett, D. A., Miller, S. A., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505846 · Cited by 127
Differentiation renders susceptibility to excitotoxicity in HT22 neurons
Suo, W., He, M., Liu, J., Cheng, S., & Xing, Y. (2013) · Neural Regeneration Research · doi:10.4103/1673-5374.121636 · Cited by 83
The effect of aged microglia on synaptic impairment and its relevance in neurodegenerative diseases
Triviño, J. J., & von Bernhardi, R. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.104982 · Cited by 43
Metadata
- Authors
- Huang, Y.-J., Lin, C.-H., Lane, H.-Y., & E. Tsaid, G.
- Venue
- Current Neuropharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012-09-01
- Volume
- 10
- Issue
- 3
- Pages
- 272-285
- ISSN
- 1570-159X (ISSN-L)
- OpenAlex
- W1991444970
- Cited by
- 85
- References
- 26
- FWCI
- 3.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.